Victory Capital Management Inc. Lowers Stock Position in Dynavax Technologies Co. (NASDAQ:DVAX)

Victory Capital Management Inc. lowered its position in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 20.4% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 240,024 shares of the biopharmaceutical company’s stock after selling 61,328 shares during the quarter. Victory Capital Management Inc. owned about 0.18% of Dynavax Technologies worth $2,695,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of DVAX. Duality Advisers LP acquired a new position in Dynavax Technologies during the first quarter valued at approximately $227,000. Boston Partners purchased a new position in shares of Dynavax Technologies in the 1st quarter valued at $292,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Dynavax Technologies by 67.8% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 25,099 shares of the biopharmaceutical company’s stock valued at $311,000 after acquiring an additional 10,143 shares in the last quarter. Diversified Trust Co boosted its position in Dynavax Technologies by 3.2% during the 1st quarter. Diversified Trust Co now owns 29,548 shares of the biopharmaceutical company’s stock worth $367,000 after purchasing an additional 925 shares during the period. Finally, Tidal Investments LLC acquired a new stake in Dynavax Technologies in the 1st quarter valued at $417,000. Institutional investors and hedge funds own 96.96% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on DVAX shares. The Goldman Sachs Group reduced their price objective on Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating on the stock in a research note on Thursday, August 8th. HC Wainwright reaffirmed a “buy” rating and issued a $29.00 price objective on shares of Dynavax Technologies in a research report on Wednesday, August 7th. Finally, StockNews.com cut shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research report on Tuesday, May 28th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $23.67.

Dynavax Technologies Price Performance

Shares of NASDAQ DVAX opened at $11.26 on Wednesday. The company has a quick ratio of 13.18, a current ratio of 14.18 and a debt-to-equity ratio of 0.35. Dynavax Technologies Co. has a fifty-two week low of $9.74 and a fifty-two week high of $15.15. The business has a 50 day moving average price of $11.00 and a two-hundred day moving average price of $11.49. The firm has a market cap of $1.47 billion, a PE ratio of 187.67 and a beta of 1.37.

Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.08 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.02. The business had revenue of $73.80 million during the quarter, compared to the consensus estimate of $76.92 million. Dynavax Technologies had a net margin of 6.88% and a return on equity of 2.76%. During the same quarter last year, the company earned $0.03 earnings per share. Sell-side analysts expect that Dynavax Technologies Co. will post 0.16 earnings per share for the current fiscal year.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.